United Kingdom of Great Britain and Northern IrelandTuberculosis profile
Population  2016 66 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.35 (0.35–0.36) 0.54 (0.53–0.54)
Mortality (HIV+TB only) 0.078 (0.038–0.13) 0.12 (0.06–0.2)
Incidence  (includes HIV+TB) 6.5 (5.9–7.2) 9.9 (8.9–11)
Incidence (HIV+TB only) 0.56 (0.33–0.85) 0.85 (0.5–1.3)
Incidence (MDR/RR-TB)** 0.11 (0.072–0.14) 0.16 (0.11–0.22)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.3 (0.27–0.33) 2.4 (2.2–2.6) 2.7 (2.4–3)
Males 0.34 (0.3–0.37) 3.5 (3.1–3.8) 3.8 (3.4–4.2)
Total 0.63 (0.57–0.7) 5.9 (5.3–6.5) 6.5 (5.9–7.2)
TB case notifications, 2016  
Total cases notified 6 175
Total new and relapse 5 793
          - % tested with rapid diagnostics at time of diagnosis 7%
          - % with known HIV status 82%
          - % pulmonary 54%
          - % bacteriologically confirmed among pulmonary 79%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 89% (81–98)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.07 (0.06–0.08)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy    
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  58
(39–78)
Estimated % of TB cases with MDR/RR-TB 1.4% (0.98–2) 3.4% (1.1–7.9)  
% notified tested for rifampicin resistance 59% 52% 3 793
MDR/RR-TB cases tested for resistance to second-line drugs   57
Laboratory-confirmed cases MDR/RR-TB: 65, XDR-TB: 7
Patients started on treatment **** MDR/RR-TB: 70, XDR-TB: 7
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 79% 5 802
Previously treated cases, excluding relapse, registered in 2015 72% 376
HIV-positive TB cases registered in 2015    
MDR/RR-TB cases started on second-line treatment in 2014 60% 53
XDR-TB cases started on second-line treatment in 2014 33% 3
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-12 Data: www.who.int/tb/data